Cystoprostatectomy specimens removed for bladder malignancy (1988 2000) at two referral centers (Mayo Clinic, Rochester, MN, The University Hospital of Innsbruck, Innsbruck, Austria) were examined for the coincidental finding of prostate cancer (PCA).
In the present study, the tetrabranched neurotensin peptide NT4 was conjugated with functional units for cancer-cell imaging or therapy and was tested on bladder cancer cell lines and specimens from bladder cancer surgical resections, in order to evaluate its potential for targeted personalized therapy of bladder cancer.
Histopathological specimens from bladder TCC patients were selected from the archive of the Department of Histopathology, the Royal London Hospital.
A further carcinoma-free prostate specimen (N 229) obtained by cystoprostatectomy for bladder cancer showed patchy methylation in RASSF1A.
In addition, normal areas were mapped for six cystoprostatectomy specimens obtained from patients undergoing treatment for bladder cancer.
Non-neoplastic controls were represented by 102 prostatic peripheral zone specimens of patients who underwent cystoprostatectomy for bladder cancer but with no tumor in prostate gland.
We also used differential expression of CD13 in the bladder stroma to isolate viable CD13-expressing stromal cells from bladder cancer specimens for further comparison.
Clearly additional studies, including examination of patient process specimens that do not host prostate cancer (such as cystoprostatectomy for bladder cancer or prostates removed for benign hypertrophy) to examine this process further.
The bladder injury was repaired surgically, and urine specimens showed A. baumannii (sensitive only to colistin, which was used for bladder irrigation) and E. faecium when cultured.
Further, the children diagnosed with squamous metaplasia were observed and treated for 1 year, followed by cystoscopy and biopsy of the bladder to obtain specimens for histopathological examination.
